|
EP2528618A4
(en)
*
|
2010-01-27 |
2015-05-27 |
Univ Indiana Res & Tech Corp |
GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
|
|
UA126465C2
(uk)
|
2011-06-10 |
2022-10-12 |
Ханмі Сайенс Ко., Лтд. |
Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
|
|
PL2721062T3
(pl)
|
2011-06-17 |
2019-05-31 |
Hanmi Science Co Ltd |
Koniugat zawierający oksyntomodulinę oraz fragment immunoglobuliny i jego zastosowanie
|
|
WO2013006486A2
(en)
|
2011-07-01 |
2013-01-10 |
Ngm Biopharmaceuticals, Inc. |
Compositions, uses and methods for treatment of metabolic disorders and diseases
|
|
MY167234A
(en)
|
2011-09-23 |
2018-08-14 |
Novo Nordisk As |
Novel glucagon analogues
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
PT2916819T
(pt)
|
2012-11-06 |
2019-10-28 |
Hanmi Pharm Ind Co Ltd |
Formulação líquida de conjugado proteico que compreende a oxintomodulina e um fragmento de imunoglobulina.
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
WO2014085365A2
(en)
|
2012-11-28 |
2014-06-05 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
IL292303A
(en)
|
2012-12-27 |
2022-06-01 |
Ngm Biopharmaceuticals Inc |
Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
MY174727A
(en)
*
|
2013-04-18 |
2020-05-11 |
Novo Nordisk As |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
|
AR096440A1
(es)
*
|
2013-05-28 |
2015-12-30 |
Takeda Pharmaceuticals Co |
Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
|
|
WO2015035419A1
(en)
*
|
2013-09-09 |
2015-03-12 |
Hoffmann-La Roche Inc. |
Dosages of gip/glp-1 co-agonist peptides for human administration
|
|
AU2014318579A1
(en)
*
|
2013-09-13 |
2016-04-14 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
SG11201602870YA
(en)
|
2013-10-28 |
2016-05-30 |
Ngm Biopharmaceuticals Inc |
Cancer models and associated methods
|
|
CN112043835B
(zh)
|
2013-12-06 |
2022-10-21 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
|
AR098616A1
(es)
|
2013-12-18 |
2016-06-01 |
Lilly Co Eli |
Péptido para el tratamiento de hipoglicemia severa
|
|
KR102455171B1
(ko)
|
2013-12-18 |
2022-10-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
|
|
PL3097122T3
(pl)
|
2014-01-24 |
2020-10-19 |
Ngm Biopharmaceuticals, Inc. |
Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
|
|
TW201625669A
(zh)
*
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
|
WO2015195509A2
(en)
|
2014-06-16 |
2015-12-23 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
US20180038869A1
(en)
*
|
2014-08-06 |
2018-02-08 |
Nestec S.A. |
Biomarkers for predicting degree of weight loss
|
|
EP3189072B1
(en)
|
2014-09-05 |
2018-07-18 |
University of Copenhagen |
Gip peptide analogues
|
|
TWI802396B
(zh)
*
|
2014-09-16 |
2023-05-11 |
南韓商韓美藥品股份有限公司 |
長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
|
|
WO2016065106A1
(en)
|
2014-10-23 |
2016-04-28 |
Ngm Biopharmaceuticals, Inc. |
Pharmaceutical compositions comprising peptide variants and methods of use thereof
|
|
CA3093383A1
(en)
|
2014-10-24 |
2016-04-28 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and glp-1 receptors
|
|
WO2016073855A1
(en)
|
2014-11-07 |
2016-05-12 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
JP2018012644A
(ja)
*
|
2014-11-26 |
2018-01-25 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
KR102418477B1
(ko)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
글루카곤 유도체
|
|
JO3575B1
(ar)
*
|
2015-01-09 |
2020-07-05 |
Lilly Co Eli |
مركبات مساعد مشترك من gip وglp-1
|
|
KR101669140B1
(ko)
*
|
2015-04-28 |
2016-10-26 |
(주)케어젠 |
항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
|
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
|
AU2016353988B2
(en)
|
2015-11-09 |
2019-09-26 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
|
US10676517B2
(en)
*
|
2016-03-10 |
2020-06-09 |
Medimmune Limited |
Glucagon and GLP-1 co-agonists for the treatment of obesity
|
|
EP3467106B1
(en)
|
2016-05-24 |
2025-07-09 |
Takeda Pharmaceutical Company Limited |
Peptide compound
|
|
WO2018039557A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
CN109200273B
(zh)
*
|
2017-07-04 |
2021-02-19 |
中国药科大学 |
一种多肽用于制备预防或治疗脂肪肝病药物的用途
|
|
JOP20190211A1
(ar)
|
2017-03-31 |
2019-09-15 |
Takeda Pharmaceuticals Co |
ببتيد منشط لمستقبل gip
|
|
WO2018220123A1
(en)
|
2017-05-31 |
2018-12-06 |
University Of Copenhagen |
Long-acting gip peptide analogues
|
|
US10470311B2
(en)
*
|
2017-09-28 |
2019-11-05 |
Juniper Networks, Inc. |
Clearance size reduction for backdrilled differential vias
|
|
IL322969A
(en)
|
2017-10-12 |
2025-10-01 |
Novo Nordisk As |
Semaglutide in medical therapy
|
|
RU2020136305A
(ru)
|
2018-05-04 |
2022-05-05 |
Ново Нордиск А/С |
Производные gip и пути их применения
|
|
KR20210024583A
(ko)
*
|
2018-07-23 |
2021-03-05 |
일라이 릴리 앤드 캄파니 |
요법을 위한 gip/glp1 공효능제 사용 방법
|
|
MX2021006505A
(es)
|
2018-12-03 |
2021-10-01 |
Antag Therapeutics Aps |
Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
|
|
CN109379770B
(zh)
*
|
2018-12-11 |
2021-04-06 |
北京百瑞互联技术有限公司 |
蓝牙mesh网络的路径辅助候选节点的优选方法、装置及节点
|
|
AU2020206388B2
(en)
*
|
2019-01-07 |
2022-12-01 |
Vitalixir (Beijing) Co., Ltd |
Novel polypeptide and therapeutic uses thereof
|
|
WO2021083306A1
(zh)
*
|
2019-10-31 |
2021-05-06 |
东莞市东阳光生物药研发有限公司 |
Glp-1/gcg双受体激动剂多肽
|
|
CA3163507A1
(en)
|
2019-12-04 |
2021-06-10 |
The Scripps Research Institute |
Peptide conjugates and methods of use
|
|
WO2021169512A1
(zh)
*
|
2020-02-24 |
2021-09-02 |
中山大学 |
多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
|
|
CN116113429A
(zh)
*
|
2020-07-06 |
2023-05-12 |
鸿绪生物医药科技（北京）有限公司 |
新型多肽及其治疗用途
|
|
CA3184723A1
(en)
*
|
2020-07-22 |
2022-01-27 |
Patrick J. KNERR |
Glp-1 and gip receptor co-agonists
|
|
AU2021312323A1
(en)
*
|
2020-07-22 |
2023-02-02 |
Novo Nordisk A/S |
Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
|
|
IL299800A
(en)
*
|
2020-08-14 |
2023-03-01 |
Hanmi Pharm Ind Co Ltd |
Pharmaceutical compositions containing long-acting conjugates of a triple agonist of the GLP-1/GIP glucagon receptor
|
|
WO2022080986A1
(ko)
*
|
2020-10-16 |
2022-04-21 |
한미약품 주식회사 |
Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
|
|
WO2022117056A1
(zh)
*
|
2020-12-02 |
2022-06-09 |
南京明德新药研发有限公司 |
含内酰胺修饰的多肽类化合物
|
|
CN114891071A
(zh)
*
|
2020-12-08 |
2022-08-12 |
鸿绪生物科技(嘉善)有限公司 |
新型多肽及其治疗用途
|
|
CN114617956B
(zh)
*
|
2020-12-10 |
2023-10-03 |
江苏中新医药有限公司 |
一种高效降糖的蛋白质药物
|
|
IL308392A
(en)
|
2021-05-13 |
2024-01-01 |
Carmot Therapeutics Inc |
G protein-coupled receptor modulators
|
|
IL309067A
(en)
*
|
2021-06-09 |
2024-02-01 |
Scripps Research Inst |
Long-acting dual gip/glp-1 peptide conjugates and methods of use
|
|
AU2022386489A1
(en)
*
|
2021-11-12 |
2024-05-23 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
|
|
TW202330584A
(zh)
|
2022-01-20 |
2023-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
前藥及其用途
|
|
CN116143884B
(zh)
*
|
2023-02-03 |
2023-08-04 |
江苏师范大学 |
一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用
|
|
TW202506170A
(zh)
*
|
2023-04-23 |
2025-02-16 |
美商卡默療法股份有限公司 |
糖尿病之治療
|
|
WO2026046202A1
(zh)
*
|
2024-08-26 |
2026-03-05 |
博瑞生物医药（苏州）股份有限公司 |
Glp-1/gip肽或含有其的药物组合物的用途
|
|
WO2026046328A1
(en)
*
|
2024-08-30 |
2026-03-05 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Dosing regimen of glp-1 conjugates
|